1. Home
  2. KZIA vs CYCN Comparison

KZIA vs CYCN Comparison

Compare KZIA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • CYCN
  • Stock Information
  • Founded
  • KZIA 1994
  • CYCN 2018
  • Country
  • KZIA Australia
  • CYCN United States
  • Employees
  • KZIA N/A
  • CYCN N/A
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • CYCN Biotechnology: Pharmaceutical Preparations
  • Sector
  • KZIA Health Care
  • CYCN Health Care
  • Exchange
  • KZIA Nasdaq
  • CYCN Nasdaq
  • Market Cap
  • KZIA 7.8M
  • CYCN 8.4M
  • IPO Year
  • KZIA 1999
  • CYCN N/A
  • Fundamental
  • Price
  • KZIA $1.29
  • CYCN $4.21
  • Analyst Decision
  • KZIA Strong Buy
  • CYCN
  • Analyst Count
  • KZIA 2
  • CYCN 0
  • Target Price
  • KZIA $11.50
  • CYCN N/A
  • AVG Volume (30 Days)
  • KZIA 5.5M
  • CYCN 5.8M
  • Earning Date
  • KZIA 03-26-2025
  • CYCN 03-04-2025
  • Dividend Yield
  • KZIA N/A
  • CYCN N/A
  • EPS Growth
  • KZIA N/A
  • CYCN N/A
  • EPS
  • KZIA N/A
  • CYCN N/A
  • Revenue
  • KZIA $1,655,324.00
  • CYCN $194,000.00
  • Revenue This Year
  • KZIA $806.89
  • CYCN N/A
  • Revenue Next Year
  • KZIA N/A
  • CYCN N/A
  • P/E Ratio
  • KZIA N/A
  • CYCN N/A
  • Revenue Growth
  • KZIA 248000.00
  • CYCN N/A
  • 52 Week Low
  • KZIA $1.25
  • CYCN $1.27
  • 52 Week High
  • KZIA $15.80
  • CYCN $9.47
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 39.50
  • CYCN 58.42
  • Support Level
  • KZIA $1.31
  • CYCN $2.81
  • Resistance Level
  • KZIA $2.64
  • CYCN $6.25
  • Average True Range (ATR)
  • KZIA 0.24
  • CYCN 0.67
  • MACD
  • KZIA 0.09
  • CYCN 0.17
  • Stochastic Oscillator
  • KZIA 14.29
  • CYCN 48.35

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: